Lantern Pharma Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Lantern Pharma Inc. (LTRN) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-20.78-15.96-14.26-12.36-5.91
Depreciation & Amortization0.020.010.010.010.00
Stock Based Compensation0.731.071.190.961.19
Change in Working Capital2.230.70-0.610.60-0.94
Change in Accounts Receivable-0.180.000.000.000.00
Change in Accounts Payable1.64-0.240.581.620.12
Change in Other Working Capital0.170.770.140.09-1.06
Other Operating Activities0.170.950.140.091.19
Net Cash from Operating Activities-17.81-14.35-12.77-10.59-5.65
Investing Activities
Capital Expenditures-0.010.02-0.03-0.02-0.02
Purchases of Investments-17.28-0.91-3.91-19.580.00
Sales/Maturities of Investments20.667.284.120.06-0.02
Other Investing Activities0.000.000.00-0.02-0.02
Net Cash from Investing Activities3.37-0.930.18-19.53-0.02
Financing Activities
Debt Repayment0.000.000.000.00-0.17
Common Stock Issued0.070.000.3069.0026.30
Common Stock Repurchased0.00-0.50-2.48-0.940.00
Other Financing Activities0.00-0.500.00-4.78-2.75
Net Cash from Financing Activities0.07-0.50-2.1863.4223.66
Summary
Effect of Forex Changes on Cash-0.05-0.03-0.010.000.00
Net Change in Cash-14.38-15.81-14.7733.2918.00
Cash at Beginning of Period21.9437.7452.5219.231.23
Cash at End of Period7.51-14.3737.7452.5219.23
Free Cash Flow-17.83-14.37-12.80-10.61-5.67